Join the next big breakthrough in reproductive health technology.
Single Use Sterile Device
Ultra thin probe equipped with an optical sensor which detects specific receptivity biomarker levels in the endometrial fluid.
Electronic Device
Medical device allowing the recording of intrauterine biomarker measurements.
optoelectronic unit, electronic circuit, and display allowing the recording of intrauterine biomarker measurements.
Decision Support Software (ML/AI)
Providing a recommendation on the optimal timing to perform the embryo transfer, by analyzing intrauterine biomarker levels and other clinical parameters of the patient.
Unfortunately IVF succes is low
Lack of uterine readiness for embryo implantation creates low success rates which affects straight in to the patients
01
Long Treatments
In average, patients pas through 3 cycles to become a mother
02
High Expenses
IVF treatments in Europe cost around 8.000€ per cycle
03
Emotional Distress
Long cycles multiple embryo lost in the process and several hormonal treatments become in a hard situation for patients, leading to anxiety, depression and matrial conflicts
04
Embryo Transfer
Is the leading cause of IVF low success, while selecting high quality embryos is now possible, ensure uterine readiness is still a challenge for IVF specialists
Meet our Team
%20en%20tama%C3%B1o%20grande.jpeg)
CEO / Co-Founder
Mónica Rodríguez de la Vega
Seedchrony inventor +20 years in life science research, postdoc in Cell Biology and Master in Biodesing
%20en%20tama%C3%B1o%20grande.jpeg)
COO / CTO / Co-Founder
Luís Artiles
AI/ML expert, Data driven innovator +20 years in business consultancy as manager and innovation director
Clinical Trial Coordinator
Julio Herrero, MD
IVF specialists. Head of the Assisted Reproduction section of the Vall d'Hebron Hospital. CEO of the Private Clinic CRA Barcelona. Editor of the Merck Atlas of Assisted Reproduction.
CFO
Anna Puigdollers, MBA
Senior CFO and Financial Consultant, with more than 15 years of experience as finance, operations and transformation director
.jpg)
Clinical Affairs Manager
Gina Abelló
Expert in developmental biology
Over 10 years of experience in project
management within research and innovation
Regulatory Affairs and QMS Manager
Sussette Padilla
Over 15 years of experience in Regulatory
Affairs and Quality Assurance for Medical
Devices
Meet our team
%20en%20tama%C3%B1o%20grande.jpeg)
Mónica de la Vega
CEO / Co-Founder
Seedchrony inventor
+20 years in life science research, postdoc in
Cell Biology and Master in Biodesing
%20en%20tama%C3%B1o%20grande.jpeg)
Luis Artiles
COO / CTO / Co-Founder
AI/ML expert, Data driven innovator
+20 years in business consultancy as
manager and innovation director
Julio Herrero, MD
Clinical Trial Coordinator
IVF specialists. Head of the Assisted Reproduction
section of the Vall d'Hebron Hospital.
CEO of the Private Clinic CRA Barcelona
Editor of the Merck Atlas of Assisted Reproduction.
Melchor Carbonell, MD
Principal Investigator
IVF specialist. Gynecologist at CRA Barcelona
and at Val d'Hebron Hospital
Expert in implantation failures and pregnancy loss.
Anna Puigdollers, MBA
CFO
Senior CFO and Financial Consultant, with more than 15 years of experience as finance, operations and transformation director
Sussette Padilla
Regulatory Affairs and QMS Manager
Over 15 years of experience in Regulatory
Affairs and Quality Assurance for Medical
Devices
.jpg)
Gina Abelló
Clinical Affairs Manager
Expert in developmental biology
Over 10 years of experience in project
management within research and innovation
Adriano Feliu
Digital Product Designer and Marketing
Graduate in Film Direction
Specialist in Marketing, Branding, UI/UX
and Digital Design
Why to invest in Seedchrony
Health
Infertility is one of the most frequent health problem in adults in reproductive age, affecting 1 in every 6 couples.
Technology
Our patented technology is first-in-class worldwide
Market
Global IVF market valued a $23.7B in 2023 and projected to reach USD $37.4B by 2030, with a CAGR of 5.9%
Integration
Easily integrated into existing IVF clinics worldwide.
Why to invest in Seedchrony
Infertility is one of the most frequent health problem in adults in reproductive age, affecting 1 in every 6 couples.
Global IVF market valued at USD $23.7B in 2023 and projected to reach USD $37.4B by 2030, with a CAGR of 5.9%
Market witnessing significant growth due to increased awareness of infertility solutions, the rise of same-sex couples, single methods, and egg freezing procedures
Easily integrated into existing IVF clinics worldwide.
We are led by industry veterans in reproductive health and biomedical engineering
Our patented technology is first-in-class worldwide
Why to invest in Seedchrony
Health
Infertility is one of the most frequent health problem in adults in reproductive age, affecting 1 in every 6 couples.
Care
Seedchrony is non-invasive and preserve endometrial integrity unlike now day methods
Global Market
Global IVF market valued at USD $23.7B in 2023 and projected to reach USD $37.4B by 2030, with a CAGR of 5.9%
Market Grow
Market witnessing significant growth due to increased awareness of infertility solutions, the rise of same-sex couples, single methods, and egg freezing procedures
Technology
Seedchrony is a First-in-class device that reads biomarker data in the uterus the same day of transfer or day before
Science
We hold an international pattern for uterine readiness for embryo transfer
Integration
Easily integrated into existing IVF clinics worldwide.
AI Algorithm
Offers accurate AI-based recommendations. This enables doctors to conduct more effective and individualized embryo transfers.
User Friendly
We collaborate with doctors and ux/ui designers to offer specialist a friendly and fast interaction with the device, software, probe and patient.
Milestones Achived
Innovation
Identification of a novel uterine readiness biomarker
Early Feasibility Study (EFS)
A successful proof of concept has been performed with the first working prototype in a First-in-human (FIH) and (EFS) at the assisted reproduction reproduction unit of the Vall d'Hebron Hospital in Barcelona (VHIR) (TRL5)
Clinical Study using MVP
Electronic Device Minimal Viable Product (MVP) developed and currently being used in the Pilot clinical study (72 IVF patients).
Data
The EFS data was used to develop the initial version of the WOI detection algorithm, and the ongoing Pilot clinical study aims to refine and validate it into a Recommendation algorithm, prior to the multicentric clinical study.
Design
Freezing design consumible and probe
Regulatory
Validated regulatory strategy
Market
Validated market strategy
Total Adressable Market
3.75B €
1 million cycles are perfomed per year in Europe, 400k cycles in usa, India 230k and China more than 500k cycles every yeaer
Everyone should fullfill their parenthood dreams
In Seedchrony
We evaluate uterine readiness for embryo implantation on the day of embryo transfer without destroying the uterine lining is a long-standing unmet need: uterine readiness is the black box in IVF.
Next Standard of Care for Embryo Transfer
Every embryo should be transferred into the uterus only if the uterine conditions are optimal for implantation. This approach ensures that every embryo has the best chance to succeed.
In Seedchrony
We evaluate uterine readiness for embryo implantation on the day of embryo transfer without destroying the uterine lining is a long-standing unmet need: uterine readiness is the black box in IVF.
Next Standard of Care for Embryo Transfer
Every embryo should be transferred into the uterus only if the uterine conditions are optimal for implantation. This approach ensures that every embryo has the best chance to succeed.
Join the next big breakthrough in reproductive health technology.
Single Use Sterile Device
Ultra thin probe equipped with an optical sensor which detects specific receptivity biomarker levels in the endometrial fluid.
Electronic Device
Medical device allowing the
recording of intrauterine biomarker measurements.
optoelectronic unit, electronic circuit, and display allowing the recording of intrauterine biomarker measurements.
Decision Support Software (ML/AI)
Providing a recommendation on the optimal timing to perform the embryo transfer, by analyzing intrauterine biomarker levels and other clinical parameters of the patient.
Why to invest in Seedchrony
Infertility is one of the most frequent health problem in adults in reproductive age, affecting 1 in every 6 couples.
Health
Technology
Our patented technology is first-in-class worldwide
Market
Global IVF market valued a $23.7B in 2023 and projected to reach USD $37.4B by 2030, with a CAGR of 5.9%
Easily integrated into existing IVF clinics worldwide.
Integration
Why to invest in Seedchrony
Health
Infertility is one of the most frequent health problem in adults in reproductive age, affecting 1 in every 6 couples.
Technology
Our patented technology is first-in-class worldwide
Market
Global IVF market valued a $23.7B in 2023 and projected to reach USD $37.4B by 2030, with a CAGR of 5.9%
Integration
Easily integrated into existing IVF clinics worldwide.